PUBLIC - Croatia, the War, and the Future
PUBLIC - Croatia, the War, and the Future
PUBLIC - Croatia, the War, and the Future
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Vermox 100 mg/5 mL oral<br />
suspension<br />
Vermox tablets 100 mg tablets<br />
oral suspension<br />
Verolax Senna film coated tablets<br />
Vesanoid soft capsules 10<br />
mg<br />
VFEND 200 mg powder for<br />
solution for infusion<br />
VFEND 40 mg/mL powder<br />
for oral suspension<br />
soft capsules<br />
powder for solution for<br />
infusion<br />
powder for oral<br />
suspension<br />
VFEND tablets 200 mg film coated tablets<br />
VFEND tablets 50 mg film coated tablets<br />
Viagra tablets 100 mg film coated tablets<br />
Viagra tablets 25 mg film coated tablets<br />
Viagra tablets 50 mg film coated tablets<br />
Videx capsules 125 mg<br />
Videx capsules 250 mg<br />
Videx capsules 400 mg<br />
Vilpin 10 mg tablets tablets<br />
Vilpin 5 mg tablets tablets<br />
gastric-resistant<br />
capsules, hard<br />
gastric-resistant<br />
capsules, hard<br />
gastric-resistant<br />
capsules, hard<br />
Krka d.d., Novo mesto,<br />
Republic of Slovenia in<br />
cooperation with<br />
Janssen<br />
Pharmaceutica,<br />
Beerse, Belgium<br />
Krka d.d., Novo mesto,<br />
Republic of Slovenia in<br />
cooperation with<br />
Janssen<br />
Pharmaceutica,<br />
Beerse, Belgium<br />
Krka d.d., Šmarješka<br />
cesta 6, Novo mesto,<br />
Republic of Slovenia<br />
F. Hoffmann-La Roche<br />
Ltd.,<br />
Grenzacherstrasse<br />
124, Basel,<br />
Switzerl<strong>and</strong><br />
Pfizer PGM, Pocé-sur-<br />
Cisse, France<br />
Pfizer PGM, Pocé-sur-<br />
Cisse, France<br />
Heinrich Mack Nachf.<br />
GmbH & Co.,<br />
Illertissen, Germany<br />
Heinrich Mack Nachf.<br />
GmbH & Co.,<br />
Illertissen, Germany<br />
Pfizer PGM, Poce-sur-<br />
Cisse, France<br />
Pfizer PGM, Poce-sur-<br />
Cisse, France<br />
Pfizer PGM, Poce-sur-<br />
Cisse, France<br />
Bristol-Myers Squibb,<br />
Meymac, France<br />
Bristol-Myers Squibb,<br />
Meymac, France<br />
Bristol-Myers Squibb,<br />
Meymac, France<br />
Pliva <strong>Croatia</strong> Ltd., Ulica<br />
grada Vukovara 49,<br />
Zagreb, Republic of<br />
<strong>Croatia</strong><br />
Pliva <strong>Croatia</strong> Ltd., Ulica<br />
grada Vukovara 49,<br />
Zagreb, Republic of<br />
<strong>Croatia</strong><br />
30 mL of suspension in an<br />
amber glass bottle with a 5<br />
mL plastic measuring spoon,<br />
supplied in a box<br />
6 (1x6) tablets in a strip<br />
(Al/PE), supplied in a box<br />
23 (2x10) tablets in a<br />
PVC/PVD//Al) blister,<br />
supplied in a box<br />
100 soft capsules in a brown<br />
plastic bottle, supplied in a<br />
box<br />
One glass vial with rubber<br />
cap <strong>and</strong> aluminum ring,<br />
containing powder, supplied<br />
in a box<br />
45 g of powder for oral<br />
suspension in a plastic bottle<br />
with a temper-evident<br />
stopper, a plastic measuring<br />
cup for solvent (23 mL), a<br />
plastic attachment for bottle<br />
neck <strong>and</strong> a plastic syringe for<br />
administration of oral<br />
suspension, supplied in a<br />
box<br />
28 (2x14) tablets in a blister<br />
(PVC/Al), supplied in a box<br />
28 (2x14) tablets in a blister<br />
(PVC/Al), supplied in a box<br />
One (1x1) film coated tablet<br />
in a blister (PVC/Al), supplied<br />
in a box<br />
One (1x1) film coated tablet<br />
in a blister (PVC/Al) supplied<br />
in a box<br />
One (1x1) film coated tablet<br />
in a blister (PVC/Al) supplied<br />
in a box<br />
30 (3x10) capsules in a<br />
PVC/PE/ACLAR/Al blister,<br />
supplied in a carton box<br />
30 (3x10) capsules in a<br />
PVC/PE/ACLAR/Al blister,<br />
supplied in a carton box<br />
30 (3x10) capsules in a<br />
PVC/PE/ACLAR/Al blister,<br />
supplied in a carton box<br />
30 (3x10) tablets in an<br />
orange PVC/PVDC//Al,<br />
supplied in a box<br />
30 (3x10) tablets in a blister<br />
(orange PVC/PVDC//Al) ,<br />
supplied in a box<br />
YES YES<br />
YES YES<br />
YES YES<br />
YES YES<br />
YES YES YES<br />
YES YES YES<br />
YES YES YES<br />
YES YES YES<br />
YES YES YES<br />
YES YES YES<br />
YES YES YES<br />
YES YES YES YES<br />
YES YES YES YES<br />
YES YES YES YES<br />
YES YES<br />
YES YES<br />
14509/11 WS/jj 394<br />
ANNEX II DGF 2A / DG K 2 EN
Change language